Loading data for KYTX — first visit, this takes a few seconds.

Kyverna Therapeutics, Inc. (KYTX)

NasdaqGS: KYTX · Real-Time Price · USD

8.48

-0.14 (-1.62%)

At close: Sep 03, 2026, 8:00 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	6.2
Market Cap	516M
Revenue (ttm)	n/a
Net Income (ttm)	-153M
	1.94
	-2.92
	n/a
	-2.72
P/B (ttm)	3.11
P/S (ttm)	0.00
Earnings Date	Nov 11, 2026

Ask	11.23
Volume	83,542
Avg. Volume (20D)	987,234
Open	8.71
Previous Close	8.62
Day's Range	8.48 - 8.78
52-Week Range	3.55 - 13.67
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About KYTX

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and K...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 9, 2024

Employees 149

Stock Exchange NasdaqGS

Ticker Symbol KYTX

Website https://kyvernatx.com

Full Company Profile

Financial Performance

In 2025, Kyverna Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -161.31M, an increase of 26.54%.

Financial Statements

Earnings Surprise

Kyverna Therapeutics has released their quarterly earnings on Aug 11, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.63 exceeds estimates by 0.05, with 38.83% YoY growth.

Next Earnings Release

Kyverna Therapeutics, Inc. is scheduled to release its earnings on Nov 11, 2026, during market hours.
Analysts project revenue of ... Upgrade

Why Price Moved

News

2 days ago · BioPharma Dive

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

1 month ago · 24/7 Wall St.

Kyverna Therapeutics Sinks 13%: Here’s Why

A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity...

1 month ago · Insider Monkey

Kyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and Beyond

Jacob Funds, a mutual fund company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The recent quarter began against the backdrop of the war in the Middle...

2 months ago · Exec Edge

FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases

By Karen Roman Imviva Biotech said the FDA cleared its Investigational New Drug application for CTA313, a dual-targeted CAR-T therapy for the treatment of B-cell-mediated autoimmune diseases. Phase 1b...

2 months ago · Motley Fool

Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?

A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook.

Page 1 of 2

Kyverna Therapeutics, Inc. (KYTX)